Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 801–900 of 1,010
Wang, J., Zhu, X., Li, Y., Zhang, P., Wang, T., & Li, M. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6091671 · Cited by 14
“*is number continues to rapidly increase and is expected to reach 152 million by 2050 [2].”
BackgroundAzarafrouz, F., Farhangian, M., Chavoshinezhad, S., Dargahi, S., Nassiri‐Asl, M., & Dargahi, L. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102262 · Cited by 13
Morin, P., Li, M., Wang, Y., Aguilar, B. J., Berlowitz, D. R., Monfared, A. A. T., Irizarry, M. C., Zhang, Q., & Xia, W. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00379-z · Cited by 14
Ramasubramanian, B., Reddy, V. S., Chellappan, V., & Ramakrishna, S. (2022) · Biosensors · doi:10.3390/bios12121176 · Cited by 13
“Au NPs have also been found to promote anti-inflammatory activities and enhance antioxidant capacity to elicit neuroprotective benefits in an AD rat model [315,316].”
BackgroundLi, Y., Fan, H., Han, X., Sun, J., Ni, M., Zhang, L., Fang, F., Zhang, W., & Ma, P. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.10.021 · Cited by 13
Amyloid precursor protein in Alzheimer's disease
Maurya, R., Bhattacharjee, G., Khambhati, K., Gohil, N., Singh, P., Mani, I., Chu, D., Ramakrishna, S., Show, P.-L., & Singh, V. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.09.006 · Cited by 15
Jung, H., Lee, Y., Lee, S., & Sohn, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020938 · Cited by 13
“Both have been implicated in impaired neuronal functioning and connectivity, resulting in a progressive loss of brain function [1,2].”
Li, S., Li, Y., Sun, W., Qin, Z., Lu, Y., Song, Y., Ga, M., Yuan, F., & Liu, Q. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116364 · Cited by 13
Zhao, Z., Wang, J., Wang, Y., Liu, X., He, K., Guo, Q., Xie, F., Huang, Q., & Li, Z. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221251 · Cited by 15
“Alzheimer’s disease (AD) is the most common type of dementia, characterized by the decline of cognitive ability and independence of routine activities [1].”
Sun, Y., Li, J., Nan, A., Li, Z., Zhong, W., Chen, L., Liu, S., Zhang, B., Zhu, Z., & Li, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192940 · Cited by 18
“Alzheimer’s disease (AD) is a neurodegenerative brain condition leading to a progressive decline of memory and other brain functions, which include abnormal deposition of amyloid-b (Ab), neurofibrillary tangles (NFTs), neuronal loss, synaptic dysfunction, neurotransmitter imbalance and neuroinflammation (1).”
BackgroundBjørge, H., Halvorsrud, L., & Goyal, A. R. (2023) · Nursing Open · doi:10.1002/nop2.1877 · Cited by 13
Singh, R. J., Hussain, J., Kaur, A., Jamdare, B. G., Pathak, D., Garg, K., Kaur, R., Shankar, S., & Sunkaria, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102002 · Cited by 17
Chu, C., Pan, W., Ren, Y., Mao, P., Yang, C., Liu, C., & Tang, Y. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1243894 · Cited by 13
Ramos, V., Reis, M. A., Ferreira, L., Silva, A. M., Ferraz, R., Vieira, M., Vasconcelos, V. M., & Martins, R. F. (2023) · Biomolecules · doi:10.3390/biom13101444 · Cited by 15
“Wistar rats, tablets of S. platensis (1500 mg/kg) revealed neuroprotective potential against brain degeneration induced by aluminum chloride (AlCl 3 ).”
BackgroundInfluentialSamuels, J. D., Lukens, J. R., & Price, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15981 · Cited by 23
“…late-onset AD (LOAD) cases are thought to be driven by a complex array of contributing factors including sex, age, genetics, socioeconomic status, comorbidities, stress, and gut microbiota composition, among many others (Breijyeh & Karaman, 2020 ; Haage & De Jager, 2022 ; Long & Holtzman, 2019 ).”
Putri, A. P. D., Ilyas, N. R. A., Abdullah, D. A. P., Pratama, F. A., Azzahra, K. S., & Permana, A. D. (2023) · Chemical Data Collections · doi:10.1016/j.cdc.2023.101106 · Cited by 13
Acharya, N. K., Grossman, H. C., Clifford, P. M., Levin, E. C., Light, K., Choi, H.-N., Swanson, R. L., Kosciuk, M. C., Venkataraman, V., Libon, D. J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231028 · Cited by 16
Zhang, H., Wu, C., Chen, X., Zhang, Z., Jiang, X., Qin, H., & Tang, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202100272 · Cited by 13
Theerasri, A., Janpaijit, S., Tencomnao, T., & Prasansuklab, A. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1591 · Cited by 14
Wei, W., Jing, L., Tian, Y., Więckowska, A., Kang, D., Meng, B., Panek, D., Godyń, J., Góral, I., Song, Y., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117535 · Cited by 13
Public Awareness, Knowledge, and Attitude Toward Alzheimer’s Disease in Makkah, Saudi Arabia
Muglan, J., Alkhaldi, R., Alsharif, M. M., Almuwallad, S. I., & Alotaibi, R. S. (2023) · Cureus · doi:10.7759/cureus.49047 · Cited by 13
“It also affects patients' families and causes an economic burden with estimated costs of US$1 trillion globally [3].”
BackgroundMemantine protects the cultured rat hippocampal neurons treated by NMDA and amyloid β1–42
Rozumna, N. M., Hanzha, V. V., & Lukyanetz, E. A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1269664 · Cited by 14
“These hallmark features primarily consist of insoluble beta-amyloid (A β ) deposits and hyperphosphorylated tau protein (Bloom, 2014; Breijyeh and Karaman, 2020; Busche and Hyman, 2020; Tyshchenko and Lukyanetz, 2020; Ashrafian et al., 2021).”
BackgroundStudy on the role and mechanism of Tan IIA in Alzheimer’s disease based on CREB-BDNF-TrkB pathway
Xiang, X., Xia, S., Zeng, Y., Wang, L., Yu, J., Liang, M., & Zhou, Y. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137769 · Cited by 14
Mitrović, N., Adžić, M., Kontić, M. Z., Dragić, M., Petrović, S., Paunović, M., Vučić, V., & Grković, I. (2024) · Cells · doi:10.3390/cells13141184 · Cited by 13
“Pathological processes can have a variety of causes, including genetic and environmental factors [2,3].”
BackgroundNanozymes in Alzheimer's disease diagnostics and therapy
Li, L., Zhang, W., Cao, H., Fang, L., Wang, W., Li, C., He, Q., Jiao, J., & Zheng, R. (2024) · Biomaterials Science · doi:10.1039/d4bm00586d · Cited by 13
Selegiline Improves Cognitive Impairment in the Rat Model of Alzheimer’s Disease
Basir, H. S., Mirazi, N., Komaki, A., Mohamadpour, B., & Hosseini, A. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04388-x · Cited by 13
Nour, H., Yamari, I., Abchır, O., Mounadi, N., Samadi, A., Belaıdı, S., & Chtita, S. (2024) · Medicinal Chemistry · doi:10.2174/0115734064318657240822064240 · Cited by 13
Jovičić, S. M. (2024) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320241289013 · Cited by 17
“89,90 Pseudo pseudo-irreversible inhibitor targeting AChE and BChE is Rivastigmine.”
BackgroundSupplementation with NAD+ Precursors for Treating Alzheimer’s Disease: A Metabolic Approach
Alghamdi, M. A., & Braidy, N. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231277 · Cited by 14
Current pharmacological treatments for neurodegenerative diseases
Shukla, A. K., Nilgirwar, P. S., & Bali, S. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28822-7.00005-2 · Cited by 11
Mitochondria-targeting by small molecules against Alzheimer's disease: A mechanistic perspective
Pal, C. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167617 · Cited by 14
Henríquez, P. A., & Araya, N. (2024) · PeerJ Computer Science · doi:10.7717/peerj-cs.2590 · Cited by 12
Reiriz, M., Beltrán-Velasco, A. I., Echeverry‐Alzate, V., Miguel, E. M., Gómez-Senent, S., Uceda, S., & Clemente‐Suárez, V. J. (2025) · Nutrients · doi:10.3390/nu17030391 · Cited by 14
Cornea, M., Vintilă, B. I., Bucuță, M. D., Ștef, L., Anghel, C. E., Grama, A. M., Lomnășan, A., Ștețiu, A. A., Boicean, A., Sava, M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051766 · Cited by 14
Potential benefits of kefir and its compounds on Alzheimer's disease: A systematic review
Tanure, Y. C. B., Mafra, A. C. M., Guimarães, B. L. M., Magalhães, R. C., Fagúndez, C., do Nascimento, I. J. B., & Brito, J. C. M. (2025) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2025.100115 · Cited by 14
SARM1: The Checkpoint of Axonal Degeneration in the Nervous System Disorders
Karnik, A., & Joshi, A. R. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04835-3 · Cited by 13
“Neuronal loss leads to sequential memory loss on account of shrinkage of the hippocampus which is involved in cognition [133].”
Issa, E. H. B., Alghazo, E. M., Gharaibeh, R., Momani, N. B., Taha, D. Z., Jaradat, R. J., Alzu’bi, A., Almahasneh, F. A., Abu‐El‐Rub, E., & Al‐Zoubi, R. M. (2025) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaf021 · Cited by 13
Deng, K., Chen, Z. B., Zhang, X., Li, Y., Cheng, F., Wang, Z., & Wang, C. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114243 · Cited by 13
Mlinarič, T., Khachatryan, E., Wittevrongel, B., Dauwe, I., Carrette, E., Roost, D. V., Achten, E., Boon, P., Meurs, A., & Hulle, M. M. V. (2025) · Communications Biology · doi:10.1038/s42003-025-08766-6 · Cited by 14
“InearlyADstages,whentherapeuticinterventionsarelikelytoreturn themostsigni fi cant effect 25 , hippocampal atrophy is commonly observed.”
Radhakrishnan, P., Viswanathan, K., Sonali, L., Suneetha, C., & Muthusamy, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050403066250904112611 · Cited by 13
Micropeptides Encoded by Noncoding RNAs: Biological Functions and Roles in Diseases
Kong, J., Su, X., Zhou, C., Lin, W., Lin, A., & Tang, J. (2025) · Research · doi:10.34133/research.0967 · Cited by 14
“…neurodegenerative disorders characterized by an abnormal accumulation of extracellular A β plaques and intracellular neurofibrillary tangles in the brain [ 206 ], which manifests itself as cognitive dysfunction in older adults, such as memory loss, abnormal thinking, and mental retardation [ 207 ].”
Madji, S., Antih, J., Tabib, M., Silvestre, C., Ghennai, A., Warnery, A., Vaillant, F. E., Bichon, F., Echalier, A., & Poucheret, P. (2025) · Analytica—A Journal of Analytical Chemistry and Chemical Analysis · doi:10.3390/analytica6040044 · Cited by 14
Liu, S., Min, Z., Liu, Y., Yang, X., Yan, H., Xu, H. E., Wu, Y., & Xu, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1656906 · Cited by 15
Auclair‐Ouellet, N., Kassem, O., Bronner, S., Oula, M.-L., & Binda, S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1699884 · Cited by 14
“…beta-amyloid is also found in the brain of healthy older adults and that the association between beta-amyloid load and dementia symptoms lessens with age support the contribution of other factors, such as tau accumulation, inflammation, as well as metabolic and cardiovascular factors (106, 112).”
Russell, J. K., Ingram, S., Teal, L. B., Lindsley, C. W., & Jones, C. K. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00592 · Cited by 12
Anesthetic‐loaded nanodroplets with focused ultrasound reduces agitation in Alzheimer's mice
Gouveia, F. V., Lea‐Banks, H., Aubert, I., Lipsman, N., Hynynen, K., & Hamani, C. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51737 · Cited by 13
Microorganism-Derived Molecules as Enzyme Inhibitors to Target Alzheimer’s Diseases Pathways
Nguyen, T. H., Wang, S., & Nguyen, V. B. (2023) · Pharmaceuticals · doi:10.3390/ph16040580 · Cited by 13
“The development of compounds can prevent or treat AD by targeting several pathogenic mechanisms [7,8].”
BackgroundZhang, K., Du, X., Gao, Y., Liu, S., & Xu, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221253 · Cited by 13
“AD is a slowly progressive neurodegenerative disease, which is characterized by insidious onset, followed by progressive cognitive decline and behavioral impairment, eventually resulting in a total loss of self-care ability [1, 2].”
Sayyed, N., Hafeez, A., Al-Abbasi, F. A., Omer, A. B., AlGhamdi, S. A., Alghamdi, A. M., Sheikh, R. A., & Kazmi, I. A. (2023) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.202200205 · Cited by 12
Alomari, O. A., Qusti, S. Y., Balgoon, M. J., Aljoud, F., Alamry, K. A., & Hussein, M. A. (2023) · Neurology International · doi:10.3390/neurolint15030061 · Cited by 14
“It is characterized by extracellular amyloid plaque deposition and intracellular neurofibrillary tangles, which lead to cognitive failure [1,2].”
BackgroundSAM-Support-Based Electrochemical Sensor for Aβ Biomarker Detection of Alzheimer’s Disease
Le, P. G., Le, H. T. N., Kim, H., & Cho, S. (2023) · Biosensors · doi:10.3390/bios13080809 · Cited by 14
“The expenditure for serving AD patients is about USD one trillion annually [2].”
InfluentialVerveris, A., Kyriakou, S., Ioannou, K., Chatzopoulou, P. S., Panayiotidis, M. I., Plioukas, M., & Christodoulou, K. (2023) · Plants · doi:10.3390/plants12183191 · Cited by 14
“With the ongoing increase and ageing of the global population, the number of sufferers is anticipated to double every five years, escalating further the vast burden AD imposes on humanity [1].”
Ibrahim, R. M., Teaima, M. H. M., El-Nabarawi, M. A., & Badawi, N. M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105885 · Cited by 15
Dendrimers—Novel Therapeutic Approaches for Alzheimer’s Disease
Mroziak, M., Kozłowski, G., Kołodziejczyk, W., Pszczołowska, M., Walczak, K., Beszłej, J. A., & Leszek, J. (2024) · Biomedicines · doi:10.3390/biomedicines12081899 · Cited by 12
“The mechanism of action of acetylcholinesterase inhibitors (AChEIs) is to block cholinesterase enzymes (AChE and butyryl-cholinesterase (BChE)) from degrading ACh, resulting in increased levels of ACh in the synaptic gap [45].”
BackgroundThe Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
Jamshidnejad-Tosaramandani, T., Kashanian, S., Babaei, M., Al-Sabri, M. H., & Schiöth, H. B. (2021) · Pharmaceuticals · doi:10.3390/ph14111136 · Cited by 12
Wang, L., Du, C., Liu, H., Qiu, W., Lü, X., Hu, Y., Li, Y., Sun, T., Chen, Y., & Sun, H. (2022) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202100910 · Cited by 12
Tok, F., Sağlık, B. N., Özkay, Y., Kaplancıklı, Z. A., & Koçyiğit‐Kaymakçıoğlu, B. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200265 · Cited by 12
Monfared, A. A. T., Stern, Y., Doogan, S., Irizarry, M. C., & Zhang, Q. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220422 · Cited by 13
Babylon, L., Schmitt, F., Franke, Y., Hubert, T., & Eckert, G. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158670 · Cited by 12
“γ-protease to form different large Aβ proteins [12] including Aβ1–40 and Aβ1–42 which may be the main triggers for AD [2,11,12].”
Silverman, M. H., Duggan, S., Bardelli, G., Sadler, B., Key, C., Medlock, M., Reynolds, L., & Wallner, B. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.71 · Cited by 12
“Alzheimer ’s Disease is a s low, progressive neurodegenerative disease that affects over 50 million people worldwide and is the most common form of dementia (7).”
BackgroundDual-Stream Subspace Clustering Network for revealing gene targets in Alzheimer's disease
Chen, M., Jia, S., Xue, M., Huang, H., Xu, Z., Yang, D., Zhu, W., & Song, Q. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106305 · Cited by 12
An interpretable deep learning framework identifies proteomic drivers of Alzheimer’s disease
Panizza, E., & Cerione, R. A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1379984 · Cited by 11
“However, the causes underlying the disease are still not known (Breijyeh et al., 2020).”
BackgroundCurrent Diagnostic and Treatment Methods of Alzheimer’s Disease: A Narrative Review
Dafre, R., & Wasnik, P. (2023) · Cureus · doi:10.7759/cureus.45649 · Cited by 13
Mesenchymal Stem Cells Applications in Alzheimer's Disease
Oyebode, O. D., & Tulay, P. (2023) · Global Medical Genetics · doi:10.1055/s-0043-1777087 · Cited by 12
“5,6 Examples of these cholin-esterase inhibitors are donepezil (it increases the level of AChE by binding to AChE reversibly, thereby inhibiting the hydrolysis of acetylcholine), rivastigmine (pseudo-irrevers-ible inhibitor that inhibits AChE and butyrylcholinesterase which breaks down…”
BackgroundInfluentialEmerging functions and therapeutic targets of IL‐38 in central nervous system diseases
Gao, Y., Cai, L., Wu, Y., Jiang, M., Zhang, Y., Ren, W., Song, Y., Li, L., Lei, Z., Wu, Y., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14550 · Cited by 12
Yang, Y., Wang, C., Xue, H., Chen, P., Li, H., & Wong, M. S. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.135452 · Cited by 11
Bhuvaneshwar, K., & Gusev, Y. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae098 · Cited by 12
“Its risk factors include age, family history and surrounding environment [11].”
BackgroundCabrera-Álvarez, J., Stefanovski, L., Martin, L., Susi, G., Maestú, F., & Ritter, P. (2024) · eNeuro · doi:10.1523/eneuro.0345-23.2023 · Cited by 14
“The interactions between these levels of analysis remain poorly understood, contributing to the limited treatment options (Breijyeh and Karaman, 2020; van Dyck et al., 2023).”
BackgroundImpact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach
Sharma, V., Sharma, P. C., Reang, J., Yadav, V., Tonk, R. K., Majeed, J., & Sharma, K. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107378 · Cited by 12
Zhang, W., Zhao, X., Bhuiyan, P., Liu, H., & Wei, H. (2024) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2024.04.002 · Cited by 12
“Moreover, cytochrome c discharge, BAX overexpression, and active caspase-3, -8, and -9 have been illustrated in the brains of HD patients and in experimental models of HD. 32 These evidence suggest that mitochondrial dysfunction-mediated apoptosis plays an important role in the pathogenesis of HD.…”
Londhe, S. G., Walhekar, V. S., Mangala, S. S., Kini, S. G., Scotti, M. T., Scotti, L., & Kumar, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16080991 · Cited by 12
“It is characterized by the gradual deterioration of neurons and is associated with advanced age [1].”
BackgroundLuo, Y., Hu, B., Yuan, Z., Bi, H., Yu, J., & Pan, Q. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118785 · Cited by 14
Milos, T., Vuić, B., Balic, N., Farkaš, V., Erjavec, G. N., Štrac, D. Š., Perković, M. N., & Pivac, N. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2400683 · Cited by 12
“The first is a pre-clinical or pre-symptomatic stage, lasting for several years or more, with characteristic mild memory loss and early pathological changes in cortex and hippocampus, but without any functional impairment in the daily activities and there are no clinical symptoms of AD [16].”
InfluentialPerri, G., Mathers, J. C., Martin-Ruiz, C. M., Parker, C., Demircan, K., Chillon, T. S., Schomburg, L., Robinson, L. A., Stevenson, E., Shannon, O. M., et al. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.09.004 · Cited by 12
Zahed, M. A., Ebrahimi, M., Barmakhshad, N., Shemshadi, S., & Parsasharif, N. (2024) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-024-00238-4 · Cited by 13
Amuthan, S. G., & Kumar, N., V (2025) · International Journal of Computational and Experimental Science and Engineering · doi:10.22399/ijcesen.739 · Cited by 11
Ultrasound-laccase pre-treatment enhances agarwood essential oil extraction and bioactivity
Ma, S., Chen, Y., Yan, T., Qin, J., & Li, G. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139654 · Cited by 11
Unraveling the mystery of citrate transporters in Alzheimer’s disease: An updated review
Mukherjee, A. G., Mishra, S., Gopalakrishnan, A. V., Kannampuzha, S., Murali, R., Wanjari, U. R., Stany, B. K., Vellingiri, B., Madhyastha, H., Deepankumar, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102726 · Cited by 12
Natural Products in Aging: Cellular Mechanisms and Emerging Therapeutics for Age‐Related Disorders
Dixit, V., Chaubey, K. K., Dayal, D., Chole, P. B., Manjunath, B. T., Bachheti, R. K., Gupta, P. C., Bachheti, A., & Worku, L. A. (2025) · Journal of Aging Research · doi:10.1155/jare/6868732 · Cited by 12
“With age progression, multiple organs, cell systems, brain volume, and weight are reduced [77].”
Jagodic, A., Kršek, A., Schleicher, L. M. S., & Batičić, L. (2025) · Gastrointestinal Disorders · doi:10.3390/gidisord7020028 · Cited by 12
“Abnormalities in the gut–brain axis communication often indicate a disruption in the coordinated network of neurotransmitters across the endocrine, intestinal, and brain systems (Figure 1) [56–58].”
Alves, R. L., Gonçalves, A., Voytyuk, I., & Harrison, D. C. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115234 · Cited by 11
Hu, H., Zhao, Y., Mao, J., He, J., Zhang, Y., Ye, H., & Yang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1561020 · Cited by 14
“However, these treatments yield limited ef fi cacy, providing only temporary symptom relief without altering the fundamental disease progression (Long and Holtzman, 2019; Breijyeh and Karaman, 2020; Marasco, 2020).”
Turgut, G. Ç., Pepe, N. A., Ekiz, Y. C., Şenol, H., & Şen, A. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500269 · Cited by 15
Ain, Q. U., Ullah, H., Taha, M., Rahim, F., Uddin, N., Khan, S., Iqbal, N., Nawaz, F., Iqbal, R., & Khan, K. M. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142615 · Cited by 13
Khodamoradi, S., Khodaei, F., Mohammadian, T., Ferdousi, A., & Rafiee, F. (2025) · Virology Journal · doi:10.1186/s12985-025-02786-8 · Cited by 11
“It is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles, primarily in the medial temporal lobe and neocortical structures regions of the brain essential for memory and cognition [2].”
Gao, Q., Zha, H., Liu, Z.-J., Wang, M., Zhang, Y., Bi, J., Wu, T.-Y., Liu, Z.-J., Wu, H., & Sun, D. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01420-y · Cited by 14
“Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is characterized by symptoms of memory loss, thinking and language problems, and unpredictable behaviors [1].”
Pandya, K., Roul, K., Tripathi, A., Belemkar, S., Sinha, A., Erol, M., & Kumar, D. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00207 · Cited by 12
Khan, S., Iqbal, T., Abass, K. S., Abdellattif, M. H., Gomha, S. M., & Zaki, M. E. A. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143421 · Cited by 11
Yang, M., Tang, X., Iqfath, M., Hernly, E., Unsihuay, D., Manchanda, P., Sharma, K. P., Qu, Z., Hu, H., Beveridge, C. H., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00144 · Cited by 12
Diagnosis of Canine Cognitive Dysfunction Syndrome: A Narrative Review
Vitturini, C., Cerquetella, M., Spaterna, A., Bazzano, M., & Marchegiani, A. (2025) · Veterinary Sciences · doi:10.3390/vetsci12080781 · Cited by 11
“One of the most important neurodegenerative disorders in humans is Alzheimer’s disease (AD), which has a huge impact on the quality of life of affected people and their relatives [6,7].”
Köksalmış, G. H., Soykan, B., Brattain, L. J., & Huang, H. (2025) · Wiley Interdisciplinary Reviews Computational Statistics · doi:10.1002/wics.70043 · Cited by 13
“Alzheimer's disease (AD) is the most common form of dementia and a rapidly growing public health concern (Breijyeh and Karaman 2020).”
Explainable Diagnosis of Alzheimer’s Disease Using Graph Kolmogorov-Arnold Networks
Ding, T. K., Xiang, D., Schubert, K. E., & Dong, L. F. (2025) · Communications in computer and information science · doi:10.1007/978-3-031-99879-9_1 · Cited by 11
Therapeutic Potential of Sodium Butyrate in Neurological and Psychiatric Disorders
Rahmani, D., Chodari, L., Kakallahpour, M., & Niknam, Z. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05428-w · Cited by 16
Sultana, O. F., Bandaru, M., Bushra, M. A., Reddy, P. H., & Reddy, A. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102957 · Cited by 12
Research Progress of Lipid Metabolism-Mediated Neuroinflammation in Alzheimer’s Disease
Shen, Y., Wang, X., Liu, X., Wang, G., Hou, X., & Zhou, X. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01648-9 · Cited by 12
“…formed by β-amyloid (Aβ) deposition, pathologi - cal phosphorylation of Tau protein, central nervous system inflammation, cholinergic system dysfunction, and oxida - tive stress injury(Mondragón-Rodríguez et al. 2013; Liu et al. 2019; Breijyeh and Karaman 2020; Yadollahikhales and Rojas 2023).”
Ye, Q., Gao, W., Feng, J., Li, X., Li, J., Yang, F., Li, L., Zi, M., Wu, X., Gao, H., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71185 · Cited by 11
“21 During this process, receptors such as triggering receptor expressed on myeloid cells 2 (TREM2) and tyrosine-protein kinase Mer expressed by microglia can recognize the above signals.”
Cao, K., Xiang, J., Dong, Y.-T., Xu, Y., & Guan, Z.-Z. (2021) · Medical Science Monitor · doi:10.12659/msm.933978 · Cited by 18
“Background Alzheimer disease (AD) is defined as significant and progressive memory loss in combination with cognitive decline and change in personality [1].”
Gupta, M. L., Kumar, A., Prasun, C., Nair, M. S., Kini, S. G., Yadav, D., & Nain, S. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2106515 · Cited by 13
“(Breijyeh & Karaman, 2020) Up to date, the root origins of AD have not been grasped, however, several suppositions have been put forth based on various pathophysiological factors observed in diseased patients, one of the most widely investigated being the cholinergic hypothesis which is linked to…”
BackgroundFocus on Alzheimer’s Disease: The Role of Fibroblast Growth Factor 21 and Autophagy
Yang, L., & Nao, J. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.11.003 · Cited by 11
Tang, Y., Zhang, D., Chang, Y., & Zheng, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00712 · Cited by 11
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.